Table 1. SAR table for JK3/32 series showing compounds contributing directly.
Core oxindole scaffold for JK3/32 shown, indicating six R-groups (R1-R6) subjected to modification, as well as a position within the core structure (A).
| Activity vs gt1b p7 (J4-JFH1 HCV), 72 hr treatment | ||||||||
|---|---|---|---|---|---|---|---|---|
![]() | ||||||||
| Compound | R1 | R2 | R4 | R5 | R6 | A | EC50 (µM) | CC50 (µM) |
| JK3-32 | Bzl | H | OMe | H | H | CH | 0.184 ± 0.089 (n = 4) | >100 |
| JK3-42 | Ph | H | OMe | H | H | CH | 0.932 ± 0.812 (n = 2) |
>4 |
| JK3-38 | H | H | OMe | H | H | CH | >4 (n = 2) |
>4 |
| 21-RS-7 | Bzl | H | OMe | H | H | N | 1.34 ± 0.37 (n = 3) |
>4 |
| 21-RS-8 | Bzl | H | H | H | H | N | 0.775 ± 0.700 (n = 2) |
>40 |
| 21-RS-9 | Ph | H | OMe | H | H | N | >40 (n = 1) |
>40 |
| 1191–104 | Bzl | OMe | H | H | H | CH | 11.33 (n = 1) |
>40 |
| 1191–112 | Bzl | H | CN | H | H | CH | >4 (n = 1) |
13.3 ± 12.4 (n = 2) |
| 1191–121 | Bzl | H | OMe | H | F | CH | 0.40 ± 0.12 (n = 2) |
12.8 |
| 1191–120 | ![]() |
H | OMe | H | H | CH | 1.42 ± 1.38 (n = 2) |
5.4 ± 4.4 (n = 2) |
| 1191–124 | ![]() |
H | OMe | F | H | CH | 0.32 ± 0.35 (n = 2) |
8.3 ± 3.9 (n = 2) |
| 1191–106 | ![]() |
H | OMe | H | H | CH | 11.58 (n = 1) |
>40 |
| 1191–137 | ![]() |
H | OMe | H | H | CH | 2.30 (n = 1) |
12.5 |
| 1191–140 | ![]() |
H | OMe | H | H | CH | 0.461 (n = 1) |
10.4 |
| 1191–141 | ![]() |
H | F | H | H | CH | >1.26 | >1.26 |
| 1191–146 | ![]() |
H | ![]() |
H | H | CH | 2.48 (n = 1) |
>12.6 |
| 1191–125 | ![]() |
H | H | F | H | CH | 0.209 (n = 1) |
12.9 |
| 1191–126 | ![]() |
H | CN | F | H | CH | 3.76 (n = 1) |
>40 |
| Additional compounds: | ||||||||
| Compound | Structure | EC50 (µM) | CC50 (µM) | |||||
| 21-RS-17 | ![]() |
1.73 ± 1.68 (n = 2) |
>4 | |||||
| R21 | ![]() |
>40 (n = 6) |
>40 | |||||












